Safety of Hepatitis A Vaccine | Hepatitis Central

Safety and Immunogenicity of Hepatitis A Vaccine in Patients With Chronic Liver Disease

table 3. Seroconversion Rates and GMT

	Timing	(n)	Seroconversion		GMC	95% Confidence Interval
	Timing	(n)	(n)	%	GMC	95% Confidence Interval

Group1: healthy adults	month 1	185	172	93.0	175	150-206
	month 2	186	162	87.1	100	87-115
	month 6	180	132	73.3	74	63-87
	month 7	167	164	98.2	1315	1086-1593
Group 2: chronic hepatitis B	month 1	43	36	83.7	93	68-127
	month 2	46	33	71.7	69	49-97
	month 6	45	23	51.1	43	31-60
	month 7	44	43	97.7	749	519-1080
Group 3: chronic hepatitis C	month 1	99	73	73.7^*	77	60-98
	month 2	97	55	56.7^*	47	38-58
	month 6	93	35	37.6^*	32	26-40
	month 7	87	82	94.3	467	345-631
Group 5: others	month 1	65	54	83.1^*	112	83-149
	month 2	66	48	72.7^*	64	50-81
	month 6	63	40	63.5	44	36-53
	month 7	63	60	95.2	562	403-783

NOTE. Month 1, etc.: blood sample obtained one month after dose 1, etc. Seroconversion rates in each group of CLD patients were compared with that in healthy subjects by Fisher’s Exact test. For calculation of GMCs, negative values were given an arbitrary value of one half the cut-off. 95% confidence interval = lower and upper 95% confidence interval. Abbreviations: GMC, geometric mean anti-HAV concentration; others, CLD of etiology other than hepatitis B or C; seroconversion, seropositive for anti-HAV with titer 33 mIU/mL. ^* P < .01.